TRNS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TRNS is not a good buy right now. The technical setup is still bearish (downtrend moving averages, MACD below zero), and near-term pattern-probability data skews slightly negative. With no bullish proprietary trading signals today and earnings approaching (2026-02-03 after hours), the risk/reward for an impatient entry is unattractive at ~$60.31. Best stance: avoid new buys here (hold only if already owned).
Trend is bearish: SMA_200 > SMA_20 > SMA_5 confirms the stock is trading below key longer-term averages. MACD histogram is -0.639 (below 0) and only ‘negatively contracting’, which suggests downside momentum is easing but not reversed. RSI(6)=43.6 is neutral-to-weak and not signaling an oversold bounce. Key levels: pivot 61.69 is immediate overhead resistance; a failure to reclaim it keeps pressure on the downside. Support sits at S1 58.74 (then S2 56.92); resistance at R1 64.63 (then R2 66.45). Pattern-based expectation is mildly negative: ~30% chance of -0.56% next day, -1.41% next week, -2.18% next month.
Intellectia Proprietary Trading Signals
Revenue growth remains strong: 2026/Q2 revenue $82.27M (+21.3% YoY). Gross margin improved to 32.53% (+4.03% YoY), a constructive sign for longer-term operating leverage if costs normalize. Options open interest is skewed toward calls (bullish-leaning positioning). Upcoming earnings on 2026-02-03 (after hours) can act as a directional catalyst if profitability rebounds toward expectations.
Profitability deteriorated sharply in the latest reported quarter: 2026/Q2 net income $1.27M (-61.4% YoY) and EPS $0.14 (-60% YoY), which can cap near-term upside until the market sees re-acceleration in earnings. Technical trend remains bearish (below key moving averages; MACD still below zero). No supportive news flow in the past week and no bullish proprietary signals today. Event risk: earnings (2026-02-03 AH) can create downside gaps if margins/earnings disappoint.
Latest quarter (2026/Q2): Revenue grew strongly to $82.27M (+21.30% YoY), but earnings contracted materially—net income fell to $1.269M (-61.38% YoY) and EPS dropped to $0.14 (-60.00% YoY). The bright spot was gross margin expansion to 32.53% (+4.03% YoY), suggesting the top-line engine is healthy, but the company still needs operating expense control / better flow-through for the market to reward the growth with a higher multiple.
No analyst rating or price target change data was provided, so recent Street revisions cannot be confirmed. From a ‘pros vs cons’ Wall Street-style view based on the fundamentals here: Pros—strong YoY revenue growth and improved gross margin can support a recovery narrative. Cons—large YoY EPS and net income decline raises questions about cost structure and near-term earnings quality, which typically keeps institutions cautious until a clean profitability inflection is visible. Politicians/congress/influential trading: no recent congress trading data available, and no notable influential buying/selling was provided.
